Ex Parte Kovesdi et al - Page 2




                 Appeal No. 2004-1259                                                                                                             
                 Application No. 09/832,355                                                                                                       


                         Claims 1, 9, 12 and 17 are illustrative of the claims on appeal and read as                                              
                 follows:                                                                                                                         
                         1.    A fusion protein comprising a first non-heparin-binding VEGF-A peptide                                             
                 portion, or a peptide portion that exhibits at least about 80% homology to a VEGF-A                                              
                 peptide portion, and a second non-VEGF peptide portion covalently associated with the                                            
                 first peptide portion, which first and second peptide portions separately promote                                                
                 angiogenesis or bone growth, and wherein the second peptide portion lacks a collagen                                             
                 binding domain.                                                                                                                  
                         9.  The fusion protein of claim 1, wherein the fusion protein is more angiogenic                                         
                 than a protein consisting essentially of the first peptide portion and/or is more                                                
                 angiogenic than a protein consisting essentially of the second peptide portion.                                                  
                         12.  The fusion protein of claim 9, wherein blood vessels resulting from                                                 
                 administration of the fusion protein to a mammalian host are associated with more                                                
                 smooth muscle cells, a greater concentration of smooth muscle cells, more endothelial                                            
                 cells, a greater concentration of endothelial cells, or any combination thereof, than                                            
                 blood vessels resulting from administration of a protein consisting essentially of the first                                     
                 peptide portion.                                                                                                                 
                         17.  The fusion protein of claim 1, wherein the second peptide portion comprises                                         
                 a peptide which promotes blood vessel wall maturation, blood vessel wall dilatation,                                             
                 blood vessel remodeling, extracellular matrix degradation, decreases blood vessel                                                
                 permeability, or any combination thereof.                                                                                        
                         The references cited by the examiner are:                                                                                
                 Gill et al. (Gill)                         6,291,667                                  Sept. 18, 2001                             
                 Rockwell et al. (Rockwell)                 5,874,542                                  Feb. 23, 1999                              
                 Davis et al. (Davis)                       WO 00/37642                                Jun. 29, 2000                              
                 Yoon et al. (Yoon), “Cloning and Cytotoxicity of Fusion Proteins of EGF and                                                      
                 Angiogenin,”  Life Sciences, Vol. 64, No.16, pp. 1435-1445 (1999)                                                                
                         References cited by Appellants are:                                                                                      
                 N. Ferrara, “VEGF: an update on biological and therapeutic aspects,” Curr. Opinion                                               
                 Biotech., Vol. 11, pp. 617-624 (2000)                                                                                            
                                                                        2                                                                         



Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  Next 

Last modified: November 3, 2007